Tumor-specific idiotype (Id) (Id)

The tumor-specific idiotype refers to the unique set of antigenic determinants located within the variable regions of the surface immunoglobulin or T-cell receptor of a neoplastic clone. Because these sequences are unique to the malignant cells and absent from normal tissues, they serve as ideal tumor-specific neoantigens for targeted immunotherapy [NEJM, 1992]. In the context of dendritic cell-based vaccines, the idiotype protein or its derived peptides are processed and presented on Major Histocompatibility Complex (MHC) molecules to T-cell receptors (TCRs). This interaction is designed to prime the immune system, specifically activating CD4+ helper and CD8+ cytotoxic T-cells to recognize and eliminate the malignant cells [Blood, 2006]. While idiotype vaccines like Dasiprotimut-T have demonstrated the ability to induce molecular remissions in clinical trials for follicular lymphoma, their widespread adoption has been limited by the logistical challenges of personalized manufacturing and the immunosuppressive nature of the tumor microenvironment [JCO, 2011].

Other names

B-cell receptor idiotypeT-cell receptor idiotypeClonal idiotypeId-peptide MHC complexTumor-specific antigen

Active immunotherapy involving the processing of the tumor-specific idiotype by dendritic cells and the subsequent presentation of idiotype-derived peptides on MHC Class I and II molecules to T-cell receptors, thereby inducing a specific cytotoxic and helper T-cell response against the malignant clone [Nature Medicine, 1999; Blood, 2006].